A recent simulation study from Austria and Switzerland, a cost–utility model was developed to simulate the cost-effectiveness of NT-proBNP-supported screening of undetected HF with and without Diabetes as well as its long-term consequences in HF population in patients from age 60 over lifetime (103). This evidence concerns the gene NPPB and diabetes mellitus.